Paul Pruett, MD
Glaucoma Specialist · Knoxville, TNNPI 1164611513
Payments from drug & device makers
Across 282 payments — averaging $192.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$27K
- Bausch & Lomb Americas Inc.$21K
- AbbVie$2K
- Alcon$832
- Sight Sciences, Inc.$432
- Tarsus Pharmaceuticals, Inc.$367
- plus $3K from 23 others
What the payments were for
- Consulting fees$2,5755%
- Speaking & faculty fees$39,70073%
- Travel & lodging$4,3538%
- Food & beverage$7,54914%
- Education$1290%
- Gifts$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 38 | $26,581 |
| Bausch & Lomb Americas Inc. | 31 | $21,308 |
| AbbVie(2 entities) | 84 | $2,210 |
| Alcon | 19 | $832 |
| Sight Sciences, Inc. | 14 | $432 |
| Tarsus Pharmaceuticals, Inc. | 16 | $367 |
| Oyster Point Pharma, Inc. | 10 | $351 |
| NEW World Medical,inc. | 9 | $342 |
| Novartis | 9 | $244 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $220 |
| Regeneron | 3 | $214 |
| Rxsight Inc | 4 | $205 |
| Aerie Pharmaceuticals, Inc. | 7 | $193 |
| Sun Pharmaceutical Industries Inc. | 10 | $186 |
| Ivantis, Inc | 3 | $130 |
| Genentech, Inc. | 1 | $88 |
| Eyepoint US, Inc. | 1 | $83 |
| Ocular Therapeutix, Inc. | 4 | $80 |
| Rayner Intraocular Lenses Limited | 4 | $71 |
| Apellis Pharmaceuticals, Inc. | 1 | $65 |
| Carl Zeiss Meditec USA, Inc. | 1 | $38 |
| Dompe US, Inc. | 2 | $37 |
| Harrow Eye, LLC | 1 | $30 |
| Thea Pharma Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Topcon Healthcare Solutions, Inc. | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Iridex Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$46,936
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$154
- TYRVAYA$144
- Hydrus Microstent$139
- PanOptix$138
- LUMIGAN$125
- COMBIGAN$125
- Tecnis IOL$125
- DURYSTA$125
- XDEMVY$122
- Rhopressa$122
- Rocklatan$122
- Kahook Dual Blade$118
- Clearpath$118
- Ahmed Glaucoma Valve$118
- Streamline$118
How this compares
Too few glaucoma specialist providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 395 | $160,667 |
| VyzultaLatanoprostene Bunod | 358 | $137,778 |
| RestasisCyclosporine | 103 | $104,110 |
| RhopressaNetarsudil Mesylate | 162 | $67,436 |
| RocklatanNetarsudil Mesylat/Latanoprost | 120 | $61,941 |
| CombiganBrimonidine Tartrate/Timolol | 108 | $41,677 |
| Latanoprost | 4,173 | $38,588 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,252 | $21,131 |
| Alphagan PBrimonidine Tartrate | 63 | $20,877 |
| Travoprost | 119 | $20,460 |
| Timolol Maleate | 2,013 | $20,146 |
| TyrvayaVarenicline Tartrate | 22 | $16,208 |
| Brinzolamide | 65 | $14,685 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 37 | $12,978 |
| XiidraLifitegrast | 19 | $12,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,210 | $327,332669 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $21,308 | $150,470377 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $193 | $129,377282 claims |
| AlconSimbrinza, Azopt | $832 | $21,19657 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $351 | $16,20822 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $26,581 | $2,62015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Knoxville
- Daryl McDanielKnoxville$4K
- Karen Fitzgerald-SheltonMurfreesboro$11K
- David RooneyNashville$5K
- Eric BrownNashville$42
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.